Opioid Use Disorder (OUD) Market Report 2025

The opioid use disorder (OUD) market size has grown rapidly in recent years. It will grow from $3.96 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increased prescription rates, pain management practices, drug marketing, stigmatization of addiction.

The opioid use disorder (OUD) market size is expected to see rapid growth in the next few years. It will grow to $6.94 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to regulatory interventions, focus on alternative pain management, expansion of treatment access, public health initiatives,. Major trends in the forecast period include technological innovations in treatment, individualized treatment approaches, integrated care models, community-based support programs, early intervention and prevention.

The increasing incidence of opioid addiction is anticipated to drive the growth of the opioid use disorder (OUD) market in the future. Opioid addiction is a medical condition defined by compulsive and chronic use of opioids, resulting in harmful effects on the body. Opioids can create feelings of euphoria and provide pain relief; however, their continued use can lead to the development of tolerance, necessitating higher doses to achieve the same effects, which may ultimately result in opioid use disorder. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based public health agency, reported a 4.1% increase in the rate of synthetic opioid drug overdoses, rising from 21.8 to 22.7 between 2021 and 2022. Therefore, the rising number of opioid addiction cases is driving the growth of the opioid use disorder (OUD) market.

The upsurge in the prevalence of chronic diseases is anticipated to propel the expansion of the opioid use disorder (OUD) market. Chronic diseases persist for a year or longer, demanding continuous medical attention and often limiting daily activities. Many chronic conditions, such as severe pain associated with cancer, arthritis, or other long-term ailments, frequently necessitate the use of opioid medications for effective pain management. For instance, projections from the National Centre for Biotechnology Information (NCBI) in January 2023 estimated a staggering 99.5% increase by the year 2050 in the number of individuals aged 50 years and older afflicted with at least one chronic illness, rising from 71.522 million in 2020 to 142.66 million. Thus, the surge in chronic disease prevalence is a driving force behind the growth of the opioid use disorder (OUD) market.

Product innovation stands out as a significant and increasingly favored trend in the opioid use disorder (OUD) market. Major companies operating within this sector are actively engaged in developing innovative products to maintain their market standing. An illustrative instance occurred in May 2023 when the U.S. Food and Drug Administration, a federal agency in the United States, granted approval for Brixadi (buprenorphine) extended-release injection to address moderate to severe cases of opioid use disorder (OUD). Brixadi is available in two dosage forms such as a weekly injection designed for patients commencing treatment with a single dose of transmucosal buprenorphine or those presently using the medication, and a monthly version tailored for individuals already receiving this treatment.

Prominent entities in the opioid use disorder (OUD) market are focused on forging strategic alliances to bolster their market position. Strategic alliances, taking diverse forms, aim to yield mutual benefits and fortify the market positions of the participating companies. An exemplar of this strategy occurred in March 2023, as Harm Reduction Therapeutics, a non-profit pharmaceutical company based in the United States, partnered with Catalent, Inc., a company specializing in developing and delivering advanced treatments globally. Within this collaboration, Catalent, Inc. will undertake the manufacturing of RiVive (3 mg), a naloxone nasal spray intended for harm reduction therapy, facilitating emergency treatment for known or suspected opioid overdose cases. This alliance was driven by the urgent need to address the ongoing opioid epidemic on a national scale. The goal behind developing an over-the-counter naloxone solution is to significantly broaden access, making naloxone more readily available to save lives imperiled by opioid overdoses.

In March 2023, the US-based pharmaceutical company Indivior plc successfully completed the acquisition of Opiant Pharmaceuticals Inc. for a total of $145 million. This strategic move is poised to enhance Indivior's product portfolio in the addiction treatment sector, fortifying its position in the market. Opiant Pharmaceuticals Inc., the acquired entity, is also based in the United States and specializes in the development of pharmaceuticals targeted at addressing opioid overdose, acute cannabinoid overdose, and opioid use disorder.

Major companies operating in the opioid use disorder (OUD) market include Pfizer Inc., Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Chiesi Pharmaceuticals S.p.A., Hikma Pharmaceuticals Plc., Mallinckrodt Pharmaceuticals, Indivior Plc., Purdue Pharma L.P, Alkermes Inc., Collegium Pharmaceutical Inc., Vanda Pharmaceuticals Inc., Camurus AB, Tris Pharma Inc., Mylan NV., Orexo US Inc., Zogenix Inc., Rhodes Pharmaceuticals L.P., Omeros Corporation, Braeburn Pharmaceuticals Inc., Adapt Pharma Inc., Titan Pharmaceuticals Inc., BioDelivery Sciences International Inc., AcelRx Pharmaceuticals Inc., KemPharm Inc.

North America was the largest region in the opioid use disorder (OUD) market in 2024. The regions covered in the opioid use disorder (oud) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the opioid use disorder (oud) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Opioid use disorder (OUD) is a chronic brain disease that stems from prolonged use of opioids, encompassing both prescription painkillers and illegal opioids. The development of opioid use disorder is influenced by a combination of genetic, environmental, and behavioral factors.

The primary medications for treating opioid use disorder (OUD) include buprenorphine, naltrexone, and methadone. Buprenorphine, classified as an opioid, is utilized in the management of opioid use disorder to mitigate cravings and alleviate withdrawal symptoms associated with opioid dependence. This medication is administered through oral and parenteral routes and is applicable across various age groups, including those aged 19 to 40, 41 to 60, and 61 and over. Distribution channels for buprenorphine include hospital pharmacies, retail pharmacies and stores, as well as online pharmacies.

The opioid use disorder (OUD) research report is one of a series of new reports that provides opioid use disorder (OUD) market statistics, including the opioid use disorder (OUD) industry's global market size, regional shares, competitors with opioid use disorder (OUD) market share, detailed opioid use disorder (OUD) market segments, market trends and opportunities, and any further data you may need to thrive in the opioid use disorder (OUD) industry. This opioid use disorder (OUD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The opioid use disorder (OUD) market consists of sales of bunavail, sublocade, suboxone, and zubsolv. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.